

H.C. WAINWRIGHT ADDS VERNON BERNARDINO TO ITS EQUITY RESEARCH TEAM

NEW YORK, December 3, 2018 - H.C. Wainwright & Co., LLC ("HCW"), a leading investment bank focused on capital markets and equity research in the Life Sciences sector, is pleased to announce that Vernon T. Bernardino has joined the firm as a Managing Director and Senior Biotechnology Analyst.

Mr. Bernardino joins HCW from Seaport Global Securities where he was a Managing Director and Senior Analyst covering the biotechnology sector. Prior to that he was a senior analyst at B. Riley FBR. Mr. Bernardino also previously held positions as a biotechnology analyst at Rodman & Renshaw, UBS Securities and Nicholas Applegate Capital Management.

"Vernon's addition to the research team underscores HCW's commitment to continue to enhance its capacity to bring innovative investment ideas to our clients," commented Mark Viklund, Chief Executive Officer of HCW. "His years of experience both as a biotechnology analyst and a scientist will add significant depth to our research franchise."

About H.C. Wainwright & Co., LLC

H.C. Wainwright & Co. is a full service investment bank dedicated to fostering the long-term success of growth companies through capital raising, strategic advisory, insightful research and the development of institutional support. The HCW team comprises experienced industry and financial professionals that have led the Firm to become a recognized leader in the capital markets. The team has been the leader in secondary market transactions for middle market companies since 2003.

Contact:

H.C. Wainwright & Co., LLC

430 Park Avenue, 4th Floor

New York, New York 10022

212-356-0500

info@hcwco.com

www.hcwco.com